ThromboGenics Announces Promising Six Month Follow-Up Results from its Phase IIb Trial of Microplasmin (MIVI III)
Results continue to support microplasmin’s potential to make a major contribution to the treatment of back of the eye disease
17-Nov-2008 -
ThromboGenics NV announced promising six month follow-up results from its Phase IIb MIVI III trial, which was designed to evaluate the safety and efficacy of microplasmin in vitrectomy. The results were presented at the American Academy of Ophthalmology in Atlanta, USA, by Dr. Kirk Packo, ...
adhesion
clinical trials
eye disease
+5